Specify Company / Ticker to Get the Summary
Dividend History ATRA
Dividend Analytics ATRA
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Atara Biotherapeutics Inc
ATRAAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Address: 1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320
Analytics
WallStreet Target Price
16.00 USDP/E Ratio
–Dividend Yield
–Financials ATRA
Results | 2019 | Dynamics |